文献速递主动脉疾病

钝性胸主动脉损伤胸主动脉腔内修复结局的系统评价

A Systematic Review on Thoracic Endovascular Repair Outcomes in Blunt Thoracic Aortic Injuries.
PubMed 文献 · J Endovasc Ther · 2024-02-18

本系统评价纳入2000年至2022年发表的35项回顾性研究、共991例钝性胸主动脉损伤患者,评估胸主动脉腔内修复的围手术期与中期随访结局。技术成功率为98.0%,30天死亡率为5.0%,脊髓缺血1.0%,卒中2.0%;中期随访死亡率和再干预率分别为2.0%和1.0%。作者认为需要更高质量的前瞻性研究。

要点

  • 当前指南推荐胸主动脉腔内修复作为钝性胸主动脉损伤的一线治疗(Class I,证据级别C)。
  • 系统评价显示技术成功率达98.0%,30天死亡率为5.0%,脊髓缺血和卒中发生率分别为1.0%和2.0%。
  • 中期随访死亡率和再干预率均较低,分别为2.0%和1.0%,支持胸主动脉腔内修复的有效性。

核心结论

  • 胸主动脉腔内修复在钝性胸主动脉损伤中显示高技术成功率和较低的早期脑血管并发症及死亡率,中期随访死亡率和再干预率也较低,且需要更高质量的前瞻性研究。

研究设计与样本

  • 系统评价检索2000年至2022年7月30日Ovid MEDLINE、EMBASE和CENTRAL数据库的英文文献。
  • 纳入报告围手术期和随访结局的观察性研究和病例系列,样本量≥5例接受胸主动脉腔内修复的钝性胸主动脉损伤患者。
  • 共纳入35项符合标准的研究,全部为回顾性设计,合计991例患者,平均年龄34.5±16.5岁(范围16-89岁)。
  • 采用纽卡斯尔-渥太华量表评估偏倚风险。

主要发现

  • 技术成功率为98.0%(OR,95%CI=0.98,0.99,p<0.001,I²=0%)。
  • 30天死亡率为5.0%(OR,95%CI=0.03,0.06,p<0.001,I²=5.56%)。
  • 脊髓缺血发生率为1.0%(OR,95%CI=0.01,0.02,p<0.001,I²=0%),卒中发生率为2.0%(OR,95%CI=0.01,0.02,p<0.001,I²=0%)。
  • 可获得的随访时间估计为29个月(范围3-119个月),期间死亡率为2.0%(OR,95%CI=0.01,0.02,p<0.001,I²=0%)。
  • 中期随访再干预率为1.0%(OR,95%CI=0.01,0.02,p<0.001,I²=10.5%)。

关键数值与推荐

  • 当前指南推荐胸主动脉腔内修复作为钝性胸主动脉损伤的一线治疗(Class I,证据级别C)。

临床怎么用

  • 当前指南推荐胸主动脉腔内修复作为钝性胸主动脉损伤的一线治疗(Class I,证据级别C)。
  • 作者认为需要更高质量的前瞻性研究。

局限性

  • 纳入的研究全部为回顾性研究设计。
  • 作者指出需要更高质量的前瞻性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Blunt thoracic aortic injury (BTAI) represents a potentially life-threatening condition and thoracic endovascular aortic repair (TEVAR) is recommended as the first-line treatment (Class I level of evidence C) by the current guidelines. The aim of this systematic review was to determine the perioperative and mid-term follow-up outcomes of patients with BTAI treated with TEVAR. MATERIALS AND METHODS: We reviewed the English literature published between 2000 and 2022, via Ovid, using MEDLINE, EMBASE, and CENTRAL databases, until July 30, 2022. Observational studies and case series, with ≥5 patients, reporting on the perioperative and follow-up outcomes of patients who underwent TEVAR for BTAI were included. The Newcastle-Ottawa Scale was used to assess the risk of bias. Primary outcomes were technical success and 30-day mortality, cerebrovascular morbidity. Secondary outcomes were mortality and re-interventions during the mid-term follow-up. RESULTS: From 5201 articles identified by the literature search, 35 eligible studies were included in this review. All studies had a retrospective study design. In total, 991 patients were included. The mean age was 34.5±16.5 years (range=16-89 years). Technical success was 98.0% (odds ratio [OR], 95% confidence interval [CI]=0.98, 0.99, p<0.001, I2=0%). Mortality at 30 days was 5.0% (OR, 95% CI=0.03, 0.06, p<0.001, I2=5.56%). Spinal cord ischemia occurred in 1.0% (OR, 95% CI=0.01, 0.02, p<0.001, I2=0%) and stroke rate was 2.0% (OR, 95% CI=0.01, 0.02, p<0.001, I2=0%). The available follow-up was estimated at 29 months (range=3-119 months) with mortality rate at 2.0% (OR, 95% CI=0.01, 0.02, p<0.001, I2=0%) and re-intervention rate at 1.0% (OR, 95% CI=0.01, 0.02, p<0.001, I2=10.5%). CONCLUSION: Thoracic endovascular aortic repair showed high technical success and low early cerebrovascular morbidity and mortality rates. In the mid-term follow-up, the estimated mortality and re-intervention rates were also low. Furthermore, higher quality prospective studies are needed.Clinical ImpactThoracic endovascular aortic repair (TEVAR) is recommended as the first line treatement in patients with blunt thoracic aortic injuries (BTAI). This systematic review of 35 retrospective studies and 991 patients showed high technical success (98.0%) with an associated 30-day mortality at 5.0% and low spinal cord ischemia (1%) and stroke rates (2.0%). Mid-term mortality and re-intervention rates reassure the effectiveness of TEVAR in BTAI cases.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Nana P, Spanos K, Behrendt CA, et al. A Systematic Review on Thoracic Endovascular Repair Outcomes in Blunt Thoracic Aortic Injuries. J Endovasc Ther. 2024. PMID: 38369733. doi:10.1177/15266028241233163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。